Phillips-Medisize has entered an agreement with a leading biotechnology company to manufacture a wearable, electronic-enabled combination product. The product is a post-phase III development-stage combination drug and device that combines two-day, single use, disposable technology for subcutaneous drug delivery.   The wearable combination product, which is replaced every two days, is about the size of a hockey puck, and can either be adhered to the patient’s body, via an adhesive patch, or worn ...